Bio News
Samsung Pharmaceutical voluntarily withdrew its application for approval of an amendment to the domestic Phase 3 clinical trial plan for GV1001, a treatment for progressive supranuclear palsy.
The Ministry of Food and Drug Safety had requested additional information during its review.
Samsung Pharmaceutical plans to address the issues and reapply for approval of the clinical trial plan.
Biobook Team
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
